Gain of Function Mutations in CgPDR1 of Candida glabrata Not Only Mediate Antifungal Resistance but Also Enhance Virulence
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
CgPdr1p is a Candida glabrata Zn(2)-Cys(6) transcription factor involved in the regulation of the ABC-transporter genes CgCDR1, CgCDR2, and CgSNQ2, which are mediators of azole resistance. Single-point mutations in CgPDR1 are known to increase the expression of at least CgCDR1 and CgCDR2 and thus to contribute to azole resistance of clinical isolates. In this study, we investigated the incidence of CgPDR1 mutations in a large collection of clinical isolates and tested their relevance, not only to azole resistance in vitro and in vivo, but also to virulence. The comparison of CgPDR1 alleles from azole-susceptible and azole-resistant matched isolates enabled the identification of 57 amino acid substitutions, each positioned in distinct CgPDR1 alleles. These substitutions, which could be grouped into three different "hot spots," were gain of function (GOF) mutations since they conferred hyperactivity to CgPdr1p revealed by constitutive high expression of ABC-transporter genes. Interestingly, the major transporters involved in azole resistance (CgCDR1, CgCDR2, and CgSNQ2) were not always coordinately expressed in presence of specific CgPDR1 GOF mutations, thus suggesting that these are rather trans-acting elements (GOF in CgPDR1) than cis-acting elements (promoters) that lead to azole resistance by upregulating specific combinations of ABC-transporter genes. Moreover, C. glabrata isolates complemented with CgPDR1 hyperactive alleles were not only more virulent in mice than those with wild type alleles, but they also gained fitness in the same animal model. The presence of CgPDR1 hyperactive alleles also contributed to fluconazole treatment failure in the mouse model. In conclusion, this study shows for the first time that CgPDR1 mutations are not only responsible for in vitro/in vivo azole resistance but that they can also confer a selective advantage under host conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Localisation of 65 non-synonymous substitutions in CgPdr1p. The eight polymorphisms present in CgPDR1 alleles from both azole-susceptible and azole-resistant isolates are indicated by grey bars. The 57 amino acid polymorphisms (from a total of 58 mutations) specific for CgPDR1 alleles from azole-resistant isolates are indicated by black bars. Putative DBD (DNA binding domain) and MHR (middle homology region) were located by Pfam analysis. ID (putative inhibitory domain) and AD (putative transcriptional activation domain) were deduced by similarity with Pdr1p and Pdr3p from S. cerevisiae [11]. The limits of these domains are indicated by amino acids position in CgPdr1p.](https://figures.cochat.ai/paper-figures/69b6baffc71c4842aa873ef304106b27/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-2.jpg)

![Figure 4 Effect of CgPDR1 expression on azole resistance. (A) Expression of CgPDR1 in a matched pair of azole-susceptible and azole-resistant isolates (DSY2235 and DSY2234), in revertant strains (“rev”) overexpressing CgPDR1 alleles from an episomal plasmid in a pdr1Δ mutant derived from DSY562 (SFY53). CgPDR1 alleles present in each strain (“DSY” for clinical strains and “rev” for revertant strains) were named according to their strain number origin. RNA was isolated from log phase cultures, slot-blotted to membranes, and hybridized with the indicated gene probes. CgACT1 served as internal control. Signals obtained in blotted membranes were quantified by counting radioactivity by phosphor imaging. Signals obtained for CgPDR1 were normalized with CgACT1 and substracted from background. Expression values represent the increase of CgPDR1 expression in revertant strains relative to the clinical isolates expressing the same CgPDR1 allele. (B) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY2235 and DSY2234, revertant strains (rev) overexpressing CgPDR1 alleles and of a pdr1Δ mutant (SFY53). Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY2235 and DSY2234, in revertant strains (rev) overexpressing CgPDR1 alleles in a pdr1Δ mutant (SFY53). Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document (National Committee for Clinical Laboratory Standards, 2002).](https://figures.cochat.ai/paper-figures/ac16b99890e140cf9efad3769d9335b6/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-4.jpg)
![Figure 5 Quantitative analysis of azole resistance in selected C. glabrata isolates. (A) Fluconazole susceptibility testing of C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Isolates were grown on YPD medium containing the drug at the indicated concentration at 30°C for two days. The indicated genotypes correspond to the following strains: DSY562 pdr1Δ: SFY92; DSY565 pdr1Δ: SFY94; DSY562 pdr1Δ+562 (standing for re-introduction of CgPDR1 from DSY562): SFY114; DSY562 pdr1Δ+565L280F (standing for re-introduction of CgPDR1 from DSY565 with L280F substitution): SFY115; DSY565pdr1Δ+562: SFY118; DSY565 pdr1Δ+565L280F: SFY119. (B) Expression of CgCDR1, CgCDR2, and CgSNQ2 in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Quantification was performed by real-time RT-PCR. The values, which are averages of four separated experiments, represent the increase in gene expression relative to DSY562 (set at 1.00). Error bars show standard deviations. (C) Immunodetection of CgCdr1p and CgCdr2p in C. glabrata clinical isolates DSY562 and DSY565 and their derivative mutants. Proteins extract were separated by SDS-10% PAGE and immunoblotted with rabbit polyclonal anti-CgCdr1p and anti-CgCdr2p antibodies as described previously [9]. MICs to fluconazole were determined by broth microdilution method in accordance with the CLSI M27-A2 document.](https://figures.cochat.ai/paper-figures/22fe62baf08b4a8880e792810b2a746e/gain-of-function-mutations-in-cgpdr1-of-candida-glabrata-not-only-mediate-figure-5.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The authors also indicate that the altered cellular sterol composition of CG156 may affect intracellular signalling and trafficking pathways, as the efflux machinery [199,211,212] and any transport proteins that are proposed to mediate azole import via facilitated diffusion [213].”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other cases of induced cross-resistance to azole drugs in C. glabrata were related to resistance against both azoles and amphotericin B [198,199,212] and related to prochloraz (an agricultural antifungal).”
From Candida glabrata Biofilms: How Far Have We Come? (2017) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BPY41 exhibited mitochondrial dysfunction”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“However, no *CgPDR1* mutation was detected in BPY41 ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“however, it is not dependent on the presence of GOF mutations in *CgPDR1* ([14](#B14)).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [14]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845 · cited 1×
“numbers of reports showing its important role in mucosal or bloodstream infections [1,2].”
BackgroundResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784 · cited 1×
“efflux pumps (for review, see [7]).”
Self-citationThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“mutations in genes involved in antibiotic resistance can be beneficial in the fitness of pathogenic bacteria [30,31].”
BackgroundA Fungal Family of Transcriptional Regulators: the Zinc Cluster Proteins
MacPherson, S., Larochelle, M., & Turcotte, B. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-06 · Cited by 612 · cited 1×
“The consensus motif is named PDRE (for pleiotropic drug resistance element) and is present in several ABC-transporter gene promoters such as PDR5, SNQ2 and YOR1 [25].”
BackgroundThe biological cost of mutational antibiotic resistance: any practical conclusions?
Andersson, D. I. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.07.002 · Cited by 472 · cited 1×
“Restoration of fitness in drugresistant bacteria is often associated with the emergence of compensatory mutations [29].”
BackgroundPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423 · cited 1×
“during patient treatment [4–6].”
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · cited 2×
“In bacteria, antimicrobial resistance is often associated with fitness costs and thus results in a competitive disadvantage against otherwise drug-susceptible bacteria within the host [28].”
BackgroundA nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343 · cited 1×
“. CgPdr1p acts as nuclear receptor by directly binding to diverse drugs and xenobiotics, such as azoles, to activate expression of efflux pumps genes resulting in multidrug resistance”
BackgroundSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 5×
“glabrata was performed as previously described [10].”
BackgroundMethodInfluentialSelf-citation
Cited by
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“…expression patterns of the downstream effector genes, with the exception of increased expression of CDR1 and PUP1, and no correlation has been found between location of the mutation and altered gene expression (Tsai et al., 2006, 2010; Ferrari et al., 2009; Caudle et al., 2011; Paul et al., 2011).”
BackgroundAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
“glabrata, as well as loss of mitochondrial functions, not only mediate antifungal (azole) resistance but also enhance virulence in animal models [41–43].”
BackgroundMultidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
“The pleiotropic class of the ATP binding cassette (ABC) transporters (PDR) include the major azole drug transporters CDR1, CDR2 , and specifically for C. glabrata also the CgSNQ2 , and confer panazole resistance [40–42, 53].”
BackgroundMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“Notably, only a few genes were commonly regulated by the GOF mutations, suggesting complex interactions of CgPDR1 with transcriptional machinery (Tsai et al. 2010; Caudle et al. 2011; Ferrari et al. 2011b).”
BackgroundInfluentialSelf-citationEfflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
“The CgPdr1p from the resistant isolates also had amino acid substitutions that conferred upregulation of CgPDR1 and azole resistance (93, 357).”
BackgroundInfluentialFluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
“glabrata).(102) Most often, it is the combination of multiple mechanisms, acquired stepwise over time, that give rise to”
BackgroundAntifungal Resistance and New Strategies to Control Fungal Infections
Vandeputte, P., Ferrari, S., & Coste, A. T. (2012) · International Journal of Microbiology · doi:10.1155/2012/713687 · Cited by 505
“Three studies have identified separate gain-of-function mutations in CgPDR1 alleles of azole-resistant strains which are responsible for constitutive high expression of CgCDR1, CgCDR2, SNQ2, and CgPDR1 itself (Figure 9) [120, 145, 146].”
BackgroundSelf-citationCandidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
“In C. glabrata, overexpression of the ABC-T efflux pumps CgCDR1, CgSNQ2, and CgPDH1 has been shown to contribute to azole resistance in clinical isolates [58,59].”
BackgroundInfluentialEmerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Self-citationPfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Regulation of multidrug resistance in pathogenic fungi
Morschhäuser, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.08.002 · Cited by 300
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Sanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
“Additional elements (6-bp repeats) were identified in this promoter; however, these elements are only required for CgCDR1 expression in the presence of a wild-type CgPDR1 allele (Raj & Edlind, 2008).”
BackgroundInfluentialSelf-citationPham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
“Despite all the effort, which included the use of advanced PacBio long-read sequencing, the only significant mutation that was found was among those already known to confer azole resistance [144].”
BackgroundShingu-Vazquez, M., & Traven, A. (2011) · Eukaryotic Cell · doi:10.1128/ec.05184-11 · Cited by 209
“linked to mitochondrial dysfunction (8, 24), and thus, the relevance of this mechanism in the clinic remains to be studied.”
BackgroundMultidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials
Hernando-Amado, S., Blanco, P., Alcalde-Rico, M., Corona, F., Reales-Calderón, J. A., Sánchez, M. B., & Martínez, J. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.007 · Cited by 212
“…17 the expression of Cdr1 and Cdr2, are associated with resistance to high levels of 18 fluconazole and also with an increase in the pathogen virulence (Ferrari et al., 2009), 19 indicating that, as it happens in the case of bacterial pathogens, resistance and 20 virulence might be interlinked.”
BackgroundMolecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S. (2023) · Cells · doi:10.3390/cells12222655 · Cited by 180
“In C. albicans Efflux pumps CDR1, SNQ2, PDH1 and QDR2 implicated in N. glabrata antifungal resistance are regulated by the Pdr1 transcription factor [132,137,150].”
BackgroundFungal resistance to echinocandins and the MDR phenomenon in Candida glabrata
Healey, K., & Perlin, D. S. (2018) · doi:10.20944/preprints201808.0306.v1 · Cited by 194
Fungal Resistance to Echinocandins and the MDR Phenomenon in Candida glabrata
Healey, K. R., & Perlin, D. S. (2018) · Journal of Fungi · doi:10.3390/jof4030105 · Cited by 194
“PDR1-mediated increased expression of EPA1 increased organ colonization in a mouse UTI model [66] and virulence in a model of hematogenous disseminated candidiasis [74,75].”
BackgroundSchwarzmüller, T., Ma, B., Hiller, E., Istel, F., Tscherner, M., Brunke, S., Ames, L., Firon, A., Green, B., Cabral, V., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004211 · Cited by 191
“glabrata utilizes a limited set of mechanisms to mount azole resistance, with ABC transporter-mediated efflux by Cdr1 and Pdh1 being the most important one, both in vitro and in vivo [32,67,99–102].”
BackgroundUpdate on Antifungal Drug Resistance
Perlin, D. S., Shor, E., & Zhao, Y. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0015-1 · Cited by 174
A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
“The exception may be in C. glabrata where azole resistance is associated with mutations in the transcription factor pdr1 (Ferrari et al., 2009), or if targeted DNA sequencing is performed for a mutation already known to confer resistance.”
BackgroundOropharyngeal candidiasis in the era of antiretroviral therapy
Thompson, G. R., Patel, P. K., Kirkpatrick, W. R., Westbrook, S. D., Berg, D., Erlandsen, J., Redding, S. W., & Patterson, T. F. (2010) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2009.11.026 · Cited by 164
Hagiwara, D., Miura, D., Shimizu, K., Paul, S., Ohba, A., Gonoi, T., Watanabe, A., Kamei, K., Shintani, T., Moye-Rowley, W. S., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006096 · Cited by 156
Roetzer, A., Gabaldón, T., & Schüller, C. (2011) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02102.x · Cited by 154
“Gain of function mutations in CgPDR1 enhances antifungal resistance and also increases virulence (Ferrari et al., 2009).”
BackgroundInhibiting fungal multidrug resistance by disrupting an activator–Mediator interaction
Nishikawa, J. L., Boeszoermenyi, A., Vale-Silva, L. A., Torelli, R., Posteraro, B., Sohn, Y.-J., Ji, F., Gelev, V., Sanglard, D., Sanguinetti, M., et al. (2016) · Nature · doi:10.1038/nature16963 · Cited by 146
Self-citationThe Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
“Pdr1p contains four do ains. u erous F utations (black bars) can cause azole resistance. o te the er ission fro Ferrari et al., 2009 [98].”
BackgroundFerrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01271-10 · Cited by 144
“CgCDR1, CgCDR2, CgSNQ2, and CgPDR1 are overexpressed in BPY41, which is consistent with the azole resistance phenotype (14, 35).”
BackgroundMethodInfluentialSelf-citationMultidrug resistance in fungi: regulation of transporter-encoding gene expression
Paul, S., & Moye-Rowley, W. S. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00143 · Cited by 137
“It has been demonstrated that some of these CgPDR1 GOF mutations also lead to hypervirulence in a mouse model for systemic candidiasis (Ferrari et al., 2009).”
BackgroundCandida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“The authors also indicate that the altered cellular sterol composition of CG156 may affect intracellular signalling and trafficking pathways, as the efflux machinery [199,211,212] and any transport proteins that are proposed to mediate azole import via facilitated diffusion [213].”
BackgroundMolecular Mechanisms of Drug Resistance in Clinical Candida Species Isolated from Tunisian Hospitals
Eddouzi, J., Parker, J. E., Vale-Silva, L. A., Coste, A., Ischer, F., Kelly, S., Manai, M., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00555-13 · Cited by 128
Self-citationFarahyar, S., Zaini, F., Kordbacheh, P., Rezaie, S., Safara, M., Raoofian, R., & Heidari, M. (2013) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-21-1 · Cited by 125
“glabrata [22-25].”
Intracellular survival of Candida glabrata in macrophages: immune evasion and persistence
Kasper, L., Seider, K., & Hube, B. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov042 · Cited by 113
Hull, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06253-11 · Cited by 113
“used in this study are ergosta 7,22-dienol (7,22), ergosterol (ERG), lanos-”
BackgroundMethodSelf-citationTreatment of Invasive Candidiasis: A Narrative Review
Ben-Ami, R. (2018) · Journal of Fungi · doi:10.3390/jof4030097 · Cited by 111
“Contrary to echinocandin resistance, fluconazole-resistance does not incur a significant fitness cost, and may in fact be associated with enhanced virulence [55].”
BackgroundContribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110
“In this study we analysed the expression profiles of GOF mutations obtained from azole-resistant isolates in a previous study [13].”
BackgroundMethodSelf-citationKsiezopolska, E., Schikora-Tamarit, M. À., Beyer, R., Nunez-Rodriguez, J. C., Schüller, C., & Gabaldón, T. (2021) · Current Biology · doi:10.1016/j.cub.2021.09.084 · Cited by 107
Espinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105
Fungal Drug Response and Antimicrobial Resistance
Osset-Trénor, P., Pascual‐Ahuir, A., & Proft, M. (2023) · Journal of Fungi · doi:10.3390/jof9050565 · Cited by 119
“According to [125], the presence of GOF mutations isolated from patients suggests that the Candida glabrata homolog Pdr1 plays an important role in the development of clinical antifungal resistance.”
BackgroundAneuploidy Enables Cross-Adaptation to Unrelated Drugs
Yang, F., Teoh, F., Tan, A. S. M., Cao, Y., Pavelka, N., & Berman, J. (2019) · Molecular Biology and Evolution · doi:10.1093/molbev/msz104 · Cited by 101
“In fact, experimental evolution of bacteria or yeast under one environmental condition sometimes leads to the acquisition of selective advantages in a second, unselected condition (Ferrari et al. 2009; Roux et al. 2015; Hampe et al. 2017).”
BackgroundResistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 122
A Xenobiotic Detoxification Pathway through Transcriptional Regulation in Filamentous Fungi
Sang, H., Hulvey, J. P., Green, R., Xu, H., Im, J., Chang, T., & Jung, G. (2018) · mBio · doi:10.1128/mbio.00457-18 · Cited by 120
Vitenshtein, A., Charpak-Amikam, Y., Yamin, R., Bauman, Y., Isaacson, B., Stein, N., Berhani, O., Dassa, L., Gamliel, M., Gur, C., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.09.008 · Cited by 96
“Protocol was based on Ferrari et al. (2009) with modifications.”
Sasse, C., Dunkel, N., Schäfer, T., Schneider, S., Dierolf, F., Ohlsen, K., & Morschhäuser, J. (2012) · Molecular Microbiology · doi:10.1111/j.1365-2958.2012.08210.x · Cited by 93
“Instead, in infection experiments in mice, genetically engineered strains containing hyperactive PDR1 alleles even exhibited increased fitness and virulence in comparison with control strains expressing wildtype PDR1 (Ferrari et al., 2009).”
BackgroundInfluentialNew antimicrobial therapies used against fungi present in subgingival sites—A brief review
Sardi, J. D. C. O., Fusco‐Almeida, A. M., & Mendes‐Giannini, M. J. S. (2011) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2011.03.007 · Cited by 103
Genomewide Expression Profile Analysis of the Candida glabrata Pdr1 Regulon
Caudle, K. E., Barker, K. S., Wiederhold, N. P., Xu, L., Homayouni, R., & Rogers, P. D. (2011) · Eukaryotic Cell · doi:10.1128/ec.00073-10 · Cited by 94
“glabrata strains expressing wild-type alleles (9).”
BackgroundMethodResultInfluentialJohnson, M. E., Katiyar, S. K., & Edlind, T. D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-10 · Cited by 91
“glabrata confer fluconazole-itraconazole cross-resistance and localize to transcription factor Pdr1, clearly distinct from the azole target, which is 14 -sterol demethylase (9, 35).”
BackgroundHull, C. M., Bader, O., Parker, J. E., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-12 · Cited by 90
“Unlike mechanisms governing azole resistance (drug efflux [5], altered ERG11 [17], and mutations in ERG3 [13]), those that influence the sensitivity of pathogenic fungi to polyenes are poorly understood.”
BackgroundSelf-citationBen-Ami, R., Zimmerman, O., Finn, T., Amit, S., Novikov, A., Wertheimer, N., Lurie-Weinberger, M., & Berman, J. (2016) · mBio · doi:10.1128/mbio.00655-16 · Cited by 88
“glabrata isolates showed evidence of a gain-of-function mutation in PDR1, which has been reported to cause full resistance to fluconazole (19).”
BackgroundDrug resistance mechanisms and their regulation in non-albicans Candida species
Kołaczkowska, A., & Kołaczkowski, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv445 · Cited by 87
Spettel, K., Barousch, W., Makristathis, A., Zeller, I., Nehr, M., Selitsch, B., Lackner, M., Rath, P.-M., Steinmann, J., & Willinger, B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210397 · Cited by 86
“…0.064 128 16 8 8 8 Cg46 multi-resistant sterile fluid FKS1 1874T>C F625S 99.68 HS 1 Garnaud (2015) 1 2 0.25 128 32 8 >16 4 PDR1 889T>C W297R 99.62 Ferrari (2009) Cg47 multi-resistant feces FKS2 1987T>C S663P 99.45 HS 1 Garnaud (2015) Beyda (2015) Zimbeck (2010) 4 16 4 128 32 4 >16 4 Cg48…”
InfluentialAzole Resistance in Candida glabrata
Whaley, S. G., & Rogers, P. D. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0554-5 · Cited by 85
Lohberger, A., Coste, A. T., & Sanglard, D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00245-13 · Cited by 85
“Enhanced virulence could be associated with a gain of fitness of strains carrying CgPDR1 GOF mutations.”
BackgroundInfluentialSelf-citationThe effect of biomaterials and antifungals on biofilm formation by Candida species: a review
Cuéllar‐Cruz, M., Vega‐González, A., Mendoza‐Novelo, B., López-Romero, E., Ruiz‐Baca, E., Escorza, M. A. Q., & Villagómez-Castro, J. C. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1634-6 · Cited by 104
Tsai, H.-F., Sammons, L. R., Zhang, X., Suffis, S. D., Su, Q., Myers, T. G., Marr, K. A., & Bennett, J. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00535-10 · Cited by 80
“glabrata can be explained by amino acid substitutions in CgPDR1 (8).”
BackgroundInfluentialHosting Infection: Experimental Models to Assay Candida Virulence
MacCallum, D. M. (2012) · International Journal of Microbiology · doi:10.1155/2012/363764 · Cited by 80
“In other virulence experiments in immunocompetent mice, where virulence was determined from fungal organ burdens at day 7 after infection, researchers were able to demonstrate that the cell wall integrity pathway [123, 124] and oxidative stress response [125], as well as the transcription factor Pdr1p and some of the…”
BackgroundCoste, A. T., Crittin, J., Bauser, C., Rohde, B., & Sanglard, D. (2009) · Eukaryotic Cell · doi:10.1128/ec.00069-09 · Cited by 79
“In contrast, the analysis of 122 Candida glabrata strains allowed discrimination of 70 distinct CgPDR1 alleles, including 12 wild-type and 58 hyperactive alleles (10).”
BackgroundResultSelf-citationRegulation of the CgPdr1 Transcription Factor from the Pathogen Candida glabrata
Paul, S., Schmidt, J. A., & Moye-Rowley, W. S. (2011) · Eukaryotic Cell · doi:10.1128/ec.00277-10 · Cited by 78
“glabrata cells also exhibit elevated CgPdr1-dependent gene expression (10, 37, 38), suggesting that CgPdr1 regulation might more closely resemble that of ScPdr3.”
BackgroundSanglard, D., & Coste, A. T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02157-15 · Cited by 77
“Paired isolates exhibited closely related genotypic patterns deduced from multilocus sequence typing (31, 40) (see Table SA1 in the supplemental maSanglard and Coste”
BackgroundSelf-citationSingh, A., Yadav, V., & Prasad, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039812 · Cited by 72
Tipping the balance both ways: drug resistance and virulence in Candida glabrata
Vale-Silva, L. A., & Sanglard, D. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov025 · Cited by 67
“Therefore, the results obtained by Ferrari et al. (2009) have so far challenged the dogma existing between development of drug resistance and fitness costs in vivo.”
InfluentialSelf-citationVerma, S., Shakya, V. P. S., & Idnurm, A. (2018) · Virulence · doi:10.1080/21505594.2017.1414133 · Cited by 67
“glabrata correlates with increased virulence and fitness of the strains expressing mutated CgPDR1 via up regulation of the efflux pump activity [85] (Fig.”
BackgroundUnderstanding the mechanisms of resistance to azole antifungals in Candida species
Li, Y., Hind, C. K., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf106 · Cited by 79
Vale-Silva, L., Ischer, F., Leibundgut-Landmann, S., & Sanglard, D. (2013) · Infection and Immunity · doi:10.1128/iai.00074-13 · Cited by 65
“glabrata led to increased fitness in vivo and increased virulence in murine models of disseminated infection (13).”
BackgroundMethodInfluentialSelf-citationMedically Important Fungi Respond to Azole Drugs: An Update
Zavřel, M., & White, T. C. (2015) · Future Microbiology · doi:10.2217/fmb.15.47 · Cited by 69
The effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 83
“It is important to note, that this in vivo fitness gain, associated with increased virulence, was absent in in vitro competition experiments, where PDR1 mutants had no selective advantage compared with azole susceptible isolates (Ferrari et al. 2009).”
InfluentialPloidy dynamics and evolvability in fungi
Wertheimer, N. B., Stone, N., & Berman, J. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0461 · Cited by 65
Brunke, S., Seider, K., Fischer, D., Jacobsen, I. D., Kasper, L., Jablonowski, N., Wartenberg, A., Bader, O., Enache-Angoulvant, A., Schaller, M., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004478 · Cited by 64
“Indeed, previous studies have elegantly shown the potential of pathogens to adapt to clinical drug regimens [4,34,35].”
BackgroundSelf-citationComparative Genomics of Two Sequential Candida glabrata Clinical Isolates
Vale-Silva, L., Beaudoing, E., Tran, V. D. T., & Sanglard, D. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.042887 · Cited by 61
“We have shown in the past years that C. glabrata azole resistance is coupled with selective fitness advantages in animal models of infection (Ferrari et al. 2009; Vale-Silva et al. 2013).”
BackgroundResultSelf-citationOrta‐Zavalza, E., Guerrero‐Serrano, G., Gutiérrez‐Escobedo, G., Cañas‐Villamar, I., Juárez‐Cepeda, J., Castaño, I., & De Las Peñas, A. (2013) · Molecular Microbiology · doi:10.1111/mmi.12247 · Cited by 61
“Interestingly, to date almost all reported mechanisms involving overexpression of those transporters engage genetic modifications, such as the acquisition of gain of function mutations in Pdr1(Ferrari et al., 2009), loss of mitochondrial function (Kaur et al.”
BackgroundInfluentialPathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Tscherner, M., Schwarzmüller, T., & Kuchler, K. (2011) · Pharmaceuticals · doi:10.3390/ph4010169 · Cited by 59
“In addition, strains harboring constitutively active PDR1 alleles also show increased virulence in mice, even in the absence of azole treatment [24].”
BackgroundWhaley, S. G., Zhang, Q., Caudle, K. E., & Rogers, P. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01070-18 · Cited by 59
“ABC transporters known to influence azole susceptibility, which do not appear to correlate with the location of the mutation (12).”
BackgroundCarreté, L., Ksiezopolska, E., Gómez-Molero, E., Angoulvant, A., Bader, O., Fairhead, C., & Gabaldón, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00112 · Cited by 58
“As shown in another study (Vale-Silva et al., 2017), the azole-resistant DSY565 presents a private non-synonymous mutation (L280F) in PDR1, which is known to mediate azole resistance in C. glabrata (Ferrari et al., 2009).”
ResultSelf-citationCastanheira, M., Deshpande, L. M., Davis, A. P., Carvalhaes, C. G., & Pfaller, M. A. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.05.004 · Cited by 63
Azole‐resistant Candida spp. – emerging pathogens?
Tobudic, S., Kratzer, C., & Presterl, E. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02146.x · Cited by 56
Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains
Popp, C., Hampe, I. A. I., Hertlein, T., Ohlsen, K., Rogers, P. D., & Morschhäuser, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00584-17 · Cited by 56
Garnaud, C., Botterel, F., Sertour, N., Bougnoux, M.-E., Dannaoui, E., Larrat, S., Hennequin, C., Guinea, J., Cornet, M., & Maubon, D. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv139 · Cited by 55
Susceptibility testing of fungi to antifungal drugs
Sanguinetti, M., & Posteraro, B. (2018) · Journal of Fungi · doi:10.3390/jof4030110 · Cited by 55
Self-citationSalazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
“An important feature of these “hyper-active” alleles is that they become active even when azoles are absent [78,85,88].”
BackgroundRecent gene selection and drug resistance underscore clinical adaptation across Candida species
Schikora-Tamarit, M. À., & Gabaldón, T. (2024) · Nature Microbiology · doi:10.1038/s41564-023-01547-z · Cited by 60
Arastehfar, A., Daneshnia, F., Zomorodian, K., Najafzadeh, M. J., Khodavaisy, S., Zarrinfar, H., Hagen, F., Zare Shahrabadi, Z., Lackner, M., Mirhendi, H., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02503-18 · Cited by 54
“…mutations in the transactivating transcription factor of C. glabrata PDR1 (Cg PDR1 ) have been considered the main cause of azole resistance in C. glabrata (10), some mutations in ERG11 are linked to MDR strains highly resistant to FLC, voriconazole (VRC), and amphotericin B (AMB) (11).”
Maiolo, E. M., Tafin, U. F., Borens, O., & Trampuž, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-14 · Cited by 64
UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata
Whaley, S. G., Caudle, K. E., Vermitsky, J.-P., Chadwick, S. G., Toner, G., Barker, K. S., Gygax, S. E., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02217-13 · Cited by 52
Molecular bases of antifungal resistance in filamentous fungi
Sharma, C., & Chowdhary, A. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.06.018 · Cited by 55
Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 51
“glabrata virulence [48], increased expression of adhesins and increased adherence to host epithelial cells [87, 102].”
BackgroundFluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008–2018
Won, E. J., Choi, M. J., Kim, M., Yong, D., Lee, W. G., Uh, Y., Kim, T. S., Byeon, S. A., Lee, S. Y., Kim, S. H., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2703.203482 · Cited by 59
“, a GOF mutation in the transcription factor for Pdr1p) (7,8).”
BackgroundResultInfluentialVale-Silva, L. A., Moeckli, B., Torelli, R., Posteraro, B., Sanguinetti, M., & Sanglard, D. (2016) · mSphere · doi:10.1128/msphere.00065-15 · Cited by 51
“glabrata strain backgrounds, including the reference strain CBS138 (ATCC 2001), whose genome was sequenced and is publicly available (26); BG2, a well-known genetic background used in several studies (7, 8, 27, 28); and DSY2235, another azole-susceptible oropharyngeal clinical isolate from our strain collection (12).”
BackgroundMethodSelf-citationPerlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
“The exception may be C. glabrata, where azole resistance is closely linked to mutations in the transcription factor PDR1 [68, 69].”
BackgroundMilbemycins: More than Efflux Inhibitors for Fungal Pathogens
Silva, L. V., Sanguinetti, M., Vandeputte, P., Torelli, R., Rochat, B., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02040-12 · Cited by 49
“This feature was dependent on the presence of a GOF mutation in CgPDR1 (9).”
BackgroundSelf-citationThe potential impact of antifungal drug resistance mechanisms on the host immune response to Candida
Lewis, R. E., Viale, P., & Kontoyiannis, D. P. (2012) · Virulence · doi:10.4161/viru.20746 · Cited by 46
“glabrata, was associated not only with higher levels of in vitro/in vivo resistance to fluconazole, but also increased virulence and “dominance” of the fungal population in mice even in the absence of drug selection.(49,50) Enhanced in vivo virulence has also been reported in other fluconazole-resistant C.”
BackgroundBiswas, C., Marcelino, V. R., Van Hal, S., Halliday, C., Martinez, E., Wang, Q., Kidd, S., Kennedy, K., Marriott, D., Morrissey, C. O., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02946 · Cited by 49
“glabrata upon fluconazole exposure (Brun et al., 2004; Ferrari et al., 2009).”
BackgroundPaul, S., Bair, T. B., & Moye-Rowley, W. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03921-14 · Cited by 45
“Given the linkage between Pdr1 activation and pathogenesis shown by others (13), we believe that characterization of the C.”
BackgroundMolecular Diagnostics for Invasive Fungal Diseases: Current and Future Approaches
Pham, D., Sivalingam, V., Tang, H. M., Montgomery, J. M., Chen, S. C. ‐., & Halliday, C. L. (2024) · Journal of Fungi · doi:10.3390/jof10070447 · Cited by 60
Posteraro, B., Martucci, R., Sorda, M. L., Fiori, B., Sanglard, D., Carolis, E. D., Florio, A. R., Fadda, G., & Sanguinetti, M. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.02070-08 · Cited by 50
Self-citationDeletion of ADA2 Increases Antifungal Drug Susceptibility and Virulence in Candida glabrata
Yu, S.-J., Chang, Y.-L., & Chen, Y.-L. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01924-17 · Cited by 43
Cavalheiro, M., Costa, C., Silva-Dias, A., Miranda, I. M., Wang, C., Pais, P., Pinto, S. N., Mil-Homens, D., Sato-Okamoto, M., Takahashi-Nakaguchi, A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-18 · Cited by 42
“the Pdr1 Y372N GOF mutation identified previously (31).”
BackgroundArastehfar, A., Daneshnia, F., Salehi, M., Yaşar, M., Hoşbul, T., Ilkit, M., Pan, W., Hagen, F., Arslan, N., Türk‐Dağı, H., et al. (2020) · Mycoses · doi:10.1111/myc.13104 · Cited by 42
Simonicova, L., & Moye-Rowley, W. S. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1009005 · Cited by 45
“The highest level of expression of both Pdr1 and Cdr1 was seen in the presence of the D1082G mutant as expected from previous work [10,11].”
BackgroundResultInfluentialHou, X., Xiao, M., Wang, H., Yu, S.-Y., Zhang, G., Zhao, Y., & Xu, Y.-C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00153-18 · Cited by 40
“None of the FR-specific polymorphisms in the present study have been reported before (9, 30).”
Background
Metadata
- Authors
- Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D.
- Affiliations
- University of Lausanne (CH)
- Università Cattolica del Sacro Cuore (IT)
- GATC Biotech (Germany) (DE)
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Sanglard, Dominique
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-01-16
- Volume
- 5
- Issue
- 1
- Pages
- e1000268
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2607542
- OpenAlex
- W2133189384
- Cited by
- 295
- References
- 46
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 24 · 2023: 12 · 2022: 19 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 25 · 2017: 19 · 2016: 17 · 2015: 12 · 2014: 22 · 2013: 18 · 2012: 14
- FWCI
- 12.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida glabrata, gain-of-function mutations, azole resistance, antifungal resistance, virulence, ABC transporters, transcription factors, clinical isolates, host fitness, trans-acting regulation
- MeSH terms
- Animals, Candidiasis, Female, Humans, Mice, Inbred BALB C, Mutation, Transcription Factors, Virulence, Fluconazole, Gene Expression Regulation, Fungal, ATP-Binding Cassette Transporters, Amino Acid Substitution, Drug Resistance, Fungal, Candida glabrata, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.